Genmab A/S FY2025 EPS Forecast Decreased by William Blair

Genmab A/S (NASDAQ:GMAB) – Equities researchers at William Blair reduced their FY2025 EPS estimates for Genmab A/S in a research report issued on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the company will post earnings of $1.38 per share for the year, down from their prior forecast of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the company earned $0.47 earnings per share.

Other analysts have also recently issued research reports about the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Down 0.8 %

Shares of GMAB opened at $21.13 on Thursday. The company’s 50 day simple moving average is $21.07 and its 200-day simple moving average is $23.96. The firm has a market cap of $13.98 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $31.88.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the period. R Squared Ltd purchased a new stake in shares of Genmab A/S during the 4th quarter worth $93,000. Blue Trust Inc. grew its stake in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.